[Efficacy of dolutegravir in treatment-naïve patients. The SPRING-1, SPRING-2, SINGLE and FLAMINGO trials].

Autor:	Bernardino JI; Hospital Universitario La Paz, IdiPAZ, Madrid, España., Antela A; Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Clínico Universitario, Santiago de Compostela, A Coruña, España. Electronic address: antonioantela@mundo-r.com.
Jazyk:	Spanish; Castilian
Zdroj:	Enfermedades infecciosas y microbiologia clinica [Enferm Infecc Microbiol Clin] 2015 Mar; Vol. 33 Suppl 1, pp. 14-9.
DOI:	10.1016/S0213-005X(15)30004-5
Abstrakt:	The efficacy of dolutegravir (DTG) in treatment-naïve patients has been analyzed in the SPRING 1 and 2, SINGLE and FLAMINGO trials, which compared dolutegravir with the agents currently recommended as the drugs of choice in clinical practice guidelines in treatment-naïve patients: efavirenz, raltegravir and darunavir/ritonavir. These trials confirmed the superiority (SINGLE and FLAMINGO) or the non-inferiority (SPRING-2) of dolutegravir. More than 2,000 patients were included in these 4 studies, lending value to their results and reinforcing the view of dolutegravir as the drug of choice in treatment-naïve patients, accompanied either by abacavir/lamivudine (Kivexa(®)) or tenofovir/emtricitabine (Truvada®). (Copyright © 2015 Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu